Advancements in the Study of Biologic Agents in Comorbidities of Psoriasis: A Literature Review

References

• Gelfand JM, Mehta NN. Aortic valve stenosis: a new cardio-vascular comorbidity of psoriasis? Eur Heart J. 2015;36(32):2134–2135. doi:10.1093/eurheartj/ehv271
   PubMed Web of Science ®Google Scholar
• Kim M, Han K, Lee J. Bodyweight variability and the risk of psoriasis: A nationwide population-based cohort study. J Eur Acad Dermatol. 2020;34(5):1019–1025. doi:10.1111/jdv.16099
   Web of Science ®Google Scholar
• Brembilla NC, Boehncke WH. Dermal adipocytes’ claim forfame in psoriasis. Exp Dermatol. 2017;26(5):392–393. doi:10.1111/exd.13074
   PubMed Web of Science ®Google Scholar
• Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007–1011. PMID: 21492252. doi:10.1111/j.1468-3083.2011.04065.x
   PubMed Web of Science ®Google Scholar
• Podoswa-Ozerkovsky N, maya-Guerra M, Barba-Gómez JF, et al. Expert recommendations for biological treatment in patients with psoriasis. Gac Med Mex. 2020;156(5):446–453. doi:10.24875/GMM.M20000441
   PubMed Web of Science ®Google Scholar
• Zafiriou E, Daponte A, Siokas V, et al. Depression and obesity in patients with psoriasis and psoriatic arthritis: is IL-17-mediated immune dysregulation the connecting link? Front Immunol. 2021;12:699848. doi:10.3389/fimmu.2021.699848
   PubMed Web of Science ®Google Scholar
• Kong ZL, Jiao TT, Zhang FR. Analysis of factors associated with psoriasis comorbid with type 2 diabetes. Chin J Lepros Skin Dis. 2021;37(2):80–84.
   Google Scholar
• Gelfand J, Wan M. Psoriasis: A novel risk factor for type2 diabetes. Lancet Diabetes Endo. 2018;6(12):919–921. doi:10.1016/S2213-8587(18)30127-X
   PubMed Web of Science ®Google Scholar
• Cai J, Cui L, Wang Y, et al. Cardiometabolic comorbidities in patients with psoriasis: focusing on risk, biological therapy, and pathogenesis. Front Pharmacol. 2021;12:774808. doi:10.3389/fphar.2021.774808
   PubMed Web of Science ®Google Scholar
• Mikhaylov D, Hashim PW, Nektalova T, et al. Systemic psoriasis therapies and comorbid disease in patients with psoriasis: a review of potential risks and benefits. J Clin Aesthet Dermatol. 2019;12:46–54.
   PubMedGoogle Scholar
• Pirowska M, Obtulowicz A, Lipko-Godlewska S, et al. The level of proinflammatory cytokines: interleukins 12,23,17 and tumor necrosis factor alpha in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis. Postepy Dermatol Alergol. 2018;35(4):360–366. doi:10.5114/ada.2018.77665
   PubMed Web of Science ®Google Scholar
• Warren R, Blauvelt A, Bagel J, et al. Bimekizumab versus Adalimumab in plaque psoriasis. New Engl J Med. 2021;385(2):130–141. doi:10.1056/NEJMoa2102388
   PubMed Web of Science ®Google Scholar
• Sieper J, Poddubnyy D, Miossec P. The IL-23–IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol. 2019;15(12):747–757. doi:10.1038/s41584-019-0294-7
   PubMed Web of Science ®Google Scholar
• Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700–712. doi:10.1136/annrheumdis-2020-217159
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Jadon DR, Bosch FVD, et al. Axial involvement in psoriatic arthritis: an update for rheumatologists. Semin Arthritis Rheumatism. 2021;51(4):880–887. doi:10.1016/j.semarthrit.2021.06.006
   PubMed Web of Science ®Google Scholar
• Hjuler KF, Bøttcher M, Vestergaard C, et al. Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis. JAMA dermatol. 2016;152(10):1173–1174. doi:10.1001/jamadermatol.2016.1984
   Web of Science ®Google Scholar
• Wu JJ, Joshi AA, Reddy SP, et al. Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis. J Eur Acad Dermatol Venereol. 2018;32:1320–1326. doi:10.1111/jdv.14951
   PubMed Web of Science ®Google Scholar
• Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76:81–90. doi:10.1016/j.jaad.2016.07.042
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Shin DB, Alavi A, et al. A Phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial). Invest Dermatol. 2020;140:85–93. doi:10.1016/j.jid.2019.07.679
   PubMed Web of Science ®Google Scholar
• Thatiparthi A, Martin A, Liu J, et al. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021;22:425–442. doi:10.1007/s40257-021-00603-w
   PubMed Web of Science ®Google Scholar
• Wu JJ, Penfold RB, Primatesta P, et al. The risk of depression, suicidal ideation, and suicide attempt in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. J Eur Acad Dermatol Venereol Jeadv. 2017;31:1168–1175. doi:10.1111/jdv.14175
   PubMed Web of Science ®Google Scholar
• Fleming P, Roubille C, Richer V, et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2015;29:1063–1070. doi:10.1111/jdv.12909
   PubMed Web of Science ®Google Scholar
• Nadeem A, Ahmad SF, Al-Harbi NO, et al. IL-17A causes depression-like symptoms via NFκB and p38MAPK signaling pathways in mice: implications for psoriasis associated depression. Cytokine. 2017;97:14–24. doi:10.1016/j.cyto.2017.05.018
   PubMed Web of Science ®Google Scholar
• Lebowitz E, Lebwohl M. Review of suicide and depression in psoriasis and management of suicide warnings in patients treated with psoriasis drugs. Skin J Cutan Med. 2019;3:72–81. doi:10.25251/skin.3.2.39
   Google Scholar
• Hölsken S, Krefting F, Schedlowski M, Sondermann W. Common fundamentals of psoriasis and depression. Acta Derm Venereol. 2021;101(11):adv00609. doi:10.2340/actadv.v101.565
   PubMedGoogle Scholar
• Takeshita J, Shin DB, Ogdie A, et al. 191 Increased risk of serious infection among patients with psoriasis: a population-based cohort study in the United Kingdom. J Invest Dermatol. 2016;136(5):S34. doi:10.1016/j.jid.2016.02.219
   PubMed Web of Science ®Google Scholar
• Podlipnik S, de la Mora L, Alsina M, et al. Pneumocystis jirovecii pneumonia in a patient with pustular psoriasis with an IL −36 RN deficiency treated with infliximab: case report and review of the literature. Australas J Dermatol. 2017;58(2):e44–e47. doi:10.1111/ajd.12489
   PubMed Web of Science ®Google Scholar
• Hayashi M, Igarashi A, Okamura K, et al. Paradoxical exacerbation of latent interstitial pneumonia by secukinumab in a patient with psoriasis vulgaris. Br J Dermatol. 2019;180:684–685. doi:10.1111/bjd.17424
   PubMed Web of Science ®Google Scholar
• Kammüller M, Tsai TF, Griffiths CE, et al. Inhibition of IL–17A by secukinumab shows no evidence of increased My-cobacterium tuberculosis infections. Clin Transl Immunol. 2017;6(8):e152. doi:10.1038/cti.2017.34
   PubMedGoogle Scholar
• Bardazzi F, Magnano M, Campanati A, et al. Biologic therapies in HIV-infected patients with psoriasis: an Italian experience. Acta Derm Venereol. 2017;97(8):989–990. doi:10.2340/00015555-2698
   PubMed Web of Science ®Google Scholar
• Nakamura M, Abrouk M, Farahnik B, et al. Psoriasis treatment in HIV–positive patients: a systematic review of systemic immunosuppressive therapies. Cutis. 2018;101(1):38.
   Web of Science ®Google Scholar
• Pangilinan MCG, Sermswan P, Asawanonda P. Use of Anti-IL-17 monoclonal antibodies in HIV patients with erythrodermic psoriasis. Case Rep Dermatol. 2020;12(2):132–137. doi:10.1159/000508781
   PubMed Web of Science ®Google Scholar
• Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53. doi:10.1016/j.jaad.2018.06.056
   PubMed Web of Science ®Google Scholar
• Montes-Torres A, Aparicio G, Rivera R, et al. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. Dermatol Treat. 2019;30(5):461–465. doi:10.1080/09546634.2018.1535690
   PubMed Web of Science ®Google Scholar
• Rob F, Rozsypal H. Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities. Dermatol Ther. 2022;35(3):e15277. doi:10.1111/dth.15277
   PubMed Web of Science ®Google Scholar
• Bonifati C, Lora V, Graceffa D, et al. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World Gastroenterol. 2016;22(28):6444–6455.
   PubMed Web of Science ®Google Scholar
• Snast I, Atzmony L, Braun M, et al. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: a retrospective cohort study and systematic review of the literature (Article). J Am Acad Dermatol. 2017;77(1):88–97(e5). doi:10.1016/j.jaad.2017.01.037
   PubMed Web of Science ®Google Scholar
• Zhao XQ, Zhu WJ, Mu Y, Xu M, Xia JX. Treatment of two cases of psoriasis comorbid with chronic hepatitis B using secukinumab [J/OL]. Chin J Dermatology Venereol. 2023;158:236–242. doi:10.23736/S2784-8671.23.07499-6
   PubMedGoogle Scholar
• Freuer D, Linseisen J, Meisinger C. Association between inflammatory bowel disease and both psoriasis and psoriatic arthritis: a bidirectional 2-sample mendelian randomization study. JAMA Dermatol. 2022;158(11):1262–1268. doi:10.1001/jamadermatol.2022.3682
   PubMed Web of Science ®Google Scholar
• Mylonas A, Conrad C. Psoriasis: classical vs.paradoxical. The yin-yang of TNF and type I interferon. Front Immunol. 2018;9:2746. doi:10.3389/fimmu.2018.02746
   PubMed Web of Science ®Google Scholar
• Revankar R, Patel H, Rojas M, Walsh S, McGee JS. Systematic review of TNFα-induced paradoxical psoriasis: treatment outcomes of switching to alternative biologic therapies in inflammatory bowel disease patients. J Dermatolog Treat. 2022;18:1–4.
   Google Scholar
• Al-Bawardy B, Shivashankar R, Proctor DD. Novel and emerging therapies for inflammatory bowel disease. Front Pharmacol. 2021;12:651415. doi:10.3389/fphar.2021.651415
   PubMed Web of Science ®Google Scholar
• Fauny M, Moulin D, D′Amico F, et al. Paradoxical gastrointestinal effects of interleukin-17 blockers. Ann Rheum Dis. 2020;79(9):1132–1138. doi:10.1136/annrheumdis-2020-217927
   PubMed Web of Science ®Google Scholar
• Spencer elizabeth A, Dolinger Michael T, Dubinsky Marla CA. Single-center experience with dupilumab for atopic or psoriasiform dermatitis in patients with inflammatory bowel disease. Dig Dis Sci. 2022;68:1121–1124. doi:10.1007/s10620-022-07684-5
   PubMed Web of Science ®Google Scholar
• Liu KL, Tsai WC, Tu HP, Lee CH. Statin use and the risk of chronic kidney disease in patients with psoriasis: a nationwide cohort study in Taiwan. PLoS One. 2020;15:8.
   Google Scholar
• Grewal SK, Wan J, Denburg MR, Shin DB, Takeshita J, Gelfand JM. The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study. Br J Dermatol. 2017;176(5):1366–1369. doi:10.1111/bjd.14961
   PubMed Web of Science ®Google Scholar
• Ren F, Zhang M, Zhang C, Sang H. Psoriasis-like inflammation induced renal dysfunction through the TLR/NF-κB signal pathway. Biomed Res Int. 2020;2020:3535264. doi:10.1155/2020/3535264
   PubMed Web of Science ®Google Scholar
• Amatore F, Villani AP, Tauber M, et al. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–483. doi:10.1111/jdv.15340
   PubMed Web of Science ®Google Scholar
• Liu T, Fan XH, Zeng YP, Qin Y, Ai SX, Li XM. Adalimumab-induced IgA nephropathy and erythroderma in a patient with psoriasis. J Adverse Drug React. 2022;24(6):332–334.
   Google Scholar
• Larquey M, Girard C, Sbidian E, Richard MA, Aubin F, Schmutz JL. Efficacy of biologics in psoriasis patients under hemodialysis. Eur J Dermatol. 2017;27:531–533. doi:10.1684/ejd.2017.3064
   PubMed Web of Science ®Google Scholar
• Lima XT, Cueva MA, Lopes EM, Alora MB. Severe Covid-19 outcomes in patients with psoriasis. J Eur Acad Dermatol Venereol. 2020;34(12):e776–e8.
   PubMed Web of Science ®Google Scholar
• Loft ND, Halling AS, Iversen L, et al. Concerns related to the coronavirus disease 2019 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: A Danish questionnaire survey. J Eur Acad Dermatol Venereol. 2020;34(12):e773–e6. doi:10.1111/jdv.16863
   PubMed Web of Science ®Google Scholar
• Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse Covid-19 outcomes in patients with psoriasis-insights from a global registry-based. Study J Allergy Clin Immunol. 2021;147(1):60–71. doi:10.1016/j.jaci.2020.10.007
   PubMed Web of Science ®Google Scholar
• Han YM. Aziguli·abudureheman. Study on the relationship between serum TNF-α, IL-1β, IL-17 levels and atherosclerosis in patients with rheumatoid arthritis. Int J Lab Med. 2018;39(03):371–373.
   Google Scholar
• Syed MN, Shah M, Shin DB, Wan MT, Winthrop KL, Gelfand JM. Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis-A meta-estimate of pivotal phase 3 trials relevant to decision making during the covid-19. Pandemic J Am Acad Dermatol. 2021;84(1):161–163. doi:10.1016/j.jaad.2020.08.095
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD–NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi:10.1016/j.jaad.2018.11.057
   PubMed Web of Science ®Google Scholar
• Diotallevi F, Campanati A, Radi G, et al. Vaccination against sars-Cov-2 and psoriasis: the three things every dermatologist should know. J Eur Acad Dermatol Venereol. 2021;35(7):e428–e30. doi:10.1111/jdv.17256
   PubMed Web of Science ®Google Scholar
• Torres T. Selective Interleukin-23 p19 inhibition: another game changer in psoriasis? Focus on risankizumab. Drugs. 2017;77(14):1493–1503. doi:10.1007/s40265-017-0794-1
   PubMed Web of Science ®Google Scholar